HIF

HIF

HIFs (Hypoxia-inducible factors) are transcription factors that react to variations in the amount of oxygen available to cells, more specifically, to reductions in oxygen, or hypoxia. The effects of hypoxia, a condition of low oxygen concentration, on the cell are mediated by the HIF signaling cascade. Oftentimes, hypoxia prevents cells from differentiating. However, hypoxia encourages the growth of blood vessels and is crucial for the development of a vascular system in both cancer tumors and embryos.Additionally, the hypoxia in wounds encourages keratinocyte migration and epithelium repair. HIFs are essential to development in general. HIF-1 gene deletion in mammals causes perinatal death. It has been demonstrated that HIF-1 is essential for chondrocyte survival and enables the cells to adapt to low oxygen environments in the growth plates of bones. Human metabolism is controlled in large part by HIF. A number of medications that function as selective HIF prolyl hydroxylase inhibitors have recently been created.

HIF related products

Structure Cat No. Product Name CAS No. Product Description
V0296 BAY 87-2243 1227158-85-1 BAY 87-2243 (BAY-87-2243) is a selective hypoxia-inducible factor-1 (HIF-1) inhibitor with potential anticancer activity.
V0298 FG-2216 (YM-311; IOX-3; YM-311) 223387-75-5 FG-2216 (YM311;IOX3; YM311) is a novel, potent, and orally bioactive inhibitor of hypoxia-inducible factor-1α (HIF) prolyl 4-hydroxylase (PHD) with the potential to treat anemia.
V0295 IOX2 931398-72-0 IOX2 is a novel and potent inhibitor of hypoxia-inducible factor (HIF-1α) prolyl hydroxylase-2 (PHD2) with considerable medical uses.
V0299 KC7F2 927822-86-4 KC7F2 is a novel and potent HIF-1 (hypoxia inducible factor-1) pathway inhibitor with potential anticancer activity.
V2691 MK-8617 1187990-87-9 MK-8617 is a novel potent, selective, orally bioavailable pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1−3 (HIF PHD1−3), which inhibits PHD1, 2, 3 with IC50 values of 1.0, 1.0 and 14 nM, respectively.
V0297 PX-478 2HCl 685898-44-6 PX-478 2HCl (PX-478 dihydrochloride) is a novel, potent and orally bioactive inhibitor of HIF-1α (hypoxia-inducible factor-1α) with potential antitumor activity.
V0293 Roxadustat (FG-4592) 808118-40-3 Roxadustat (FG4592, ASP1517) is a novel, potent and orally bioavailable inhibitor of HIF-PH (hypoxia-inducible factor prolyl hydroxylase) with the potential to treat anemia associated with chronic kidney disease (CKD).
Contact Us